A light exposure tracker designed to improve the circadian entrainment for Alzheimer Disease patients

一种光暴露跟踪器，旨在改善阿尔茨海默病患者的昼夜节律变化

• 批准号: 10707191
• 负责人: Erik Page
• 金额: $ 122.97万
• 依托单位: BLUE IRIS LABS, INC.
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-15 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10707191
• 关键词: Address; Aging; Agitation; Alzheimer' s Disease; Alzheimer' s disease patient; Alzheimer' s disease related dementia; Area; Assessment tool; Automation; Caregivers; Cellular Phone; Characteristics; Circadian Dysregulation; Circadian Rhythms; Clinical Trials; Cognition; Companions; Controlled Environment; Darkness; Data; Data Collection; Data Storage and Retrieval; Dementia; Development; Devices; Disease; Elderly; Exposure to; Eye; Family; Feedback; Future; Goals; Health; Home; Human; Individual; Industry; Infrastructure; Internet; Intervention; Knowledge; Laboratories; Laboratory Study; Life; Light; Lighting; Maps; Measurement; Measures; Melatonin; Monitor; Moods; Neural Pathways; Neurosecretory Systems; Patients; Pattern; Personal Satisfaction; Persons; Phase; Phototherapy; Population; Process; Recommendation; Recording of previous events; Research; Research Personnel; Retinal Photoreceptors; Risk Reduction; Scientist; Sleep; Sleep Disorders; Small Business Innovation Research Grant; System; Technology; Testing; United States National Institutes of Health; Visualization; Wakefulness; Work; alertness; circadian; circadian pacemaker; cognitive testing; cohort; commercialization; cost effective; dashboard; design; digital; effectiveness testing; experience; exposed human population; field study; improved; improvement on sleep; interest; light intensity; mild cognitive impairment; negative affect; novel; response; sleep quality; success; tool; wireless

Project Summary The NIH has recognized the importance of circadian rhythms and sleep in Alzheimer’s disease (AD) and related dementias (ADRD) progression, recently releasing a Notice of Special Interest titled “Sleep Disorders and Circadian Clock Disruption in Alzheimer’s Disease and other Dementias of Aging.” The NIH has also noted that improving sleep quality is among the few interventions that people can take to reduce the risk of developing AD/ADRD later in life. Light therapy has shown great promise as a non-pharmacological treatment in helping to regulate sleep and in improving cognition in older adults with AD/ADRD. Perhaps not surprisingly given our evolutionary history, studies in this area can be simply summarized as: bright days and dark nights are beneficial for human health generally and AD/ADRD health specifically. Studies have demonstrated that daytime light exposure can consolidate and increase nighttime sleep efficiency, while also increasing daytime wakefulness and reducing evening agitation in AD/ADRD patients. But critical knowledge gaps exist, including information on the light exposure humans typically experience—at both individual and population levels—and how these vary from optimal light exposure patterns. Also missing are tools to collect these data and tools for individuals, researchers, and caregivers to monitor and control light exposure. In order to address these gaps, researchers have developed a novel, cost-effective, battery-powered light spectrometer which can measure circadian light characteristics and be discreetly mounted to walls or used as a wearable. This networked device provides continuous, remote data collection and storage, allowing interested parties to easily monitor circadian lighting conditions and adjust their lighting as needed. This project would build on these researcher-oriented tools and technologies to commercialize a new consumer- oriented version of this light exposure tracking system targeting patients with mild cognitive impairment (MCI) or early stage Alzheimer’s disease still living at home. Light exposure data collected by these systems would be used to provide actional recommendations and/or automations to improve circadian entrainment and overall health of AD/ADRD patients. The work proposed here will focus on the development of a new light exposure tracker, companion apps, and dashboards that gather much of the same detailed lighting data as the researcher- oriented device, but present these data in ways that are understandable and helpful for people with AD/ADRD and their caregivers. Integrations with related connected products, such as sleep trackers and smart lamps, will also be investigated. A clinical trial is proposed that includes both MCI and AD/ADRD patients living at home. The trial will characterize the light exposure that these cohorts experience and test a variety of interventions intended to bring their light exposure patterns more in line with patterns known to support circadian health.

项目摘要 美国国立卫生研究院已经认识到昼夜节律和睡眠在阿尔茨海默病(AD)及其相关疾病中的重要性 痴呆症(ADRD)进展，最近发布了一份特别令人感兴趣的通知，题为“睡眠障碍和 阿尔茨海默病和其他老年痴呆症的生物钟紊乱。美国国立卫生研究院也注意到 改善睡眠质量是人们可以采取的为数不多的降低患病风险的干预措施之一。 AD/ADRD的晚年生活。光疗法作为一种非药物疗法在帮助 调节睡眠，改善老年AD/ADRD患者的认知功能。也许并不令人惊讶，因为我们的 在进化史上，这方面的研究可以简单地概括为：白天和黑夜都是有益的 对于人类健康，特别是AD/ADRD健康。研究表明，白天的光线 暴露可以巩固和提高夜间睡眠效率，同时还可以增加白天的清醒和 减少AD/ADRD患者的夜间躁动。但关键的知识差距仍然存在，包括关于 人类通常经历的光暴露--无论是在个人层面还是群体层面--以及它们是如何变化的 从最佳的光曝光模式。同样缺失的还有收集这些数据的工具和个人使用的工具， 研究人员和护理人员，以监测和控制光暴露。为了解决这些差距，研究人员 已经开发出一种新型的、经济实惠的电池供电的光谱仪，它可以测量昼夜节律光 并可谨慎地安装在墙上或作为可穿戴设备使用。此联网设备可提供 持续的远程数据收集和存储，使感兴趣的各方能够轻松监控昼夜节律照明 并根据需要调整照明条件。 该项目将建立在这些面向研究人员的工具和技术的基础上，将新的消费者商业化- 这个面向轻度认知障碍(MCI)患者的光暴露跟踪系统的定向版本 或者早期的阿尔茨海默氏症仍然住在家里。这些系统收集的光曝光数据将是 用于提供行动建议和/或自动化，以改善昼夜节律夹带和总体 AD/ADRD患者的健康状况。这里提出的工作将集中在开发一种新的光曝光 跟踪器、配套应用程序和仪表板收集与研究人员相同的详细照明数据- 以设备为导向，但以AD/ADRD患者可以理解并有帮助的方式呈现这些数据 和他们的照顾者。与相关互联产品的集成，如睡眠跟踪器和智能灯，将 也被调查。建议进行一项临床试验，包括MCI和AD/ADRD患者，他们都住在家里。 这项试验将描述这些队列经历的光线暴露的特征，并测试各种干预措施 旨在使他们的光暴露模式更符合支持昼夜健康的已知模式。